Figure 2.
Anti-CD28 mAb prevents GVHD lethality in a myeloablative model of T-cell–replete marrow transplantation. Lethally irradiated (1200 cGy) B10.BR recipients were given transplants of 15 × 106 T cell–depleted marrow cells plus 25 × 106 splenocytes from B6 donors. Recipients were treated intraperitoneally with the indicated anti-CD28 mAb (αCD28) dose once on day 0, or every other day × 8, or with control antibody (ctrl.). Numbers of recipients are indicated in parentheses. Data were pooled from 2 experiments.
